Table 1: Experimental Gene Therapy of Neurological Disorders Using HSV Vectors

Pathological Disturbances/Clinical Indications	Therapeutic Transgenes	Stage	Ref.
Replication-Defective Vectors
Epilepsy	FGF-2, BDNF	Preclinical	[35]
Multiple sclerosis	IL-4, IL-1ra	Preclinical	[34, 48, 49]
Alzheimer’s disease	shRNA, neprilysin	Preclinical	[36]
Parkinson’s disease	GDNF bcl-2 Erithropoietin	Preclinical	[51, 52] [50, 51] [37]
Diabetes	Neurotrophic factors	Preclinical	[56-60]
Chronic pain	Preproenkephalin	Phase I	[38, 39, 88]
Lysosomal storage diseases: Tay-Sachs	HexA α subunit	Preclinical	[42]
Replication-Competent Vectors
Lysosomal disorders: MPS VII	β-glucoronidase	Preclinical	[41]
Multiple sclerosis	IL-4, IL-10	Preclinical	[76]
Ischemic brain injury	HSV-2 ICP0PK	Preclinical	[77]
Chronic pain	Preproenkephalin	Preclinical	[69, 70]